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background: Cardiolipin (CL) is a phospholipid localized to the inner mitochondrial (MITO) membrane, is essential for oxidative phosphorylation 
(OX-PHOS) and is synthesized by CL synthase 1 (CLS1) and remodeled by Tafazzin1 (TAZ1), monolysocardiolipin acyltransferase- (MLCLAT1) and acyl-
CoA:lysocardiolipin acyltransferase-1 (ALCAT1). We showed that CL and ATP synthesis are reduced in LV myocardium of dogs with heart failure (HF) 
and restored after chronic therapy with Bendavia (BEN). This study examined the effects of BEN on mRNA expression of CLS1, TAZ1, MLCLAT1 and 
ALCAT1 and protein levels of TAZ1 and ALCAT1 in LV of dogs with microembolization-induced HF.
Methods: 12 HF dogs were randomized to 3 months therapy with subcutaneous injections of BEN (0.5 mg/kg once daily, n=7) or saline (Control, 
n=7). LV tissue was obtained from all study dogs and from 6 normal (NL) dogs. mRNA expression was measured by real-time PCR, normalized to 
GAPDH and expressed as fold changes. Protein levels were measured with Western blots and expressed in densitometric units (du).
results: Compared to NL, mRNA expression of TAZ1 and CLS1 decreased in Controls while mRNA of MLCLAT1 and ALCAT1 increased (Table). Protein 
level of TAZ1 decreased in Controls and that of ALCAT1 increased. Treatment with BEN normalized expression of all genes and proteins.
conclusions: Dysregulation of CL synthesizing/remodeling enzymes exist in HF. Therapy with BEN reverses these maladaptations allowing for 
improved OX-PHOS.
NL HF-Control HF-BEN
TAZ1 mRNA (Fold change)
TAZ1 Protein Level (du)
1.0
0.69 ± 0.04
2.25 (decrease)*
0.36 ± 0.04*
1.23 (decrease)†
0.58 ± 0.04†
MLCLAT1 mRNA (Fold change) 1.0 2.60 (increase)* 1.18 (increase)†
ALCAT1 mRNA (Fold change)
ALCAT1 Protein Level (du)
1.0
0.28 ± 0.03
3.56 (increase)*
0.54 ± 0.02*
1.54 (increase)†
0.37 ± 0.03†
CLS1 mRNA (Fold change) 1.0 2.19 (decrease)* 1.39 (decrease)†
*=p<0.05 vs. NL; †=p<0.05 vs. HF-Control
